



HAL
open science

Combined cetuximab and trastuzumab are superior to gemcitabine in the treatment of human pancreatic carcinoma xenografts.

Christelle Larbouret, Bruno Robert, Caroline Bascoul-Mollevis, Frédérique Penault-Llorca, Alexandre Ho-Pun-Cheung, Sébastien Morisseau, Isabelle Navarro-Teulon, Jean-Pierre Mach, André Pèlerin, David Azria

► **To cite this version:**

Christelle Larbouret, Bruno Robert, Caroline Bascoul-Mollevis, Frédérique Penault-Llorca, Alexandre Ho-Pun-Cheung, et al.. Combined cetuximab and trastuzumab are superior to gemcitabine in the treatment of human pancreatic carcinoma xenografts.. *Annals of Oncology*, 2010, 21 (1), pp.98-103. <10.1093/annonc/mdp496>. <inserm-00431431>

HAL Id: inserm-00431431

<https://inserm.hal.science/inserm-00431431v1>

Submitted on 12 Nov 2010

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



HAL Authorization

Fig 1







Fig 2



Day post graft

- - ● - - Continuous injection of gemcitabine
- - ▲ - - Cetuximab+trastuzumab after progression under gemcitabine

Fig 3




Fig 4

